Dr Barbara Villarini will present a research seminar entitled: SmartTarget®: Minimally-Invasive Therapies for the Diagnosis and Treatment of Prostate Cancer at New Cavendish Street Campus, Room CG.03.
Dr Barbara Villarini will present her research work which she was involved in at the UCL Centre for Medical Image Computing, on the development and clinical evaluation of a regulatory-approved, software-based system, called SmartTarget®, for guiding needle biopsy and minimally-invasive therapies for the diagnosis and treatment of prostate cancer.
Prostate cancer is the most common form of cancer in men in the western world and a leading cause of cancer-related death. The aim of the project was to provide a low-cost clinical tool for accurately targeting tumours that are visible in MRI images but not visible in ultrasound images used routinely to guide biopsy and minimally-invasive therapies.
The system is currently used in clinical trials undertaken by the UCLH Urology Team. A key feature is a state-of-the-art algorithm for deformable registration of MRI, transrectal and ultrasound images of the prostate. This algorithm accounts for tissue motion due to pressure from the transrectal ultrasound probe, which deforms the prostate gland and leads to a different shape compared with its appearance in MRI images. Additionally, to understand the efficacy of MRI-to-TRUS image registration, to produce comparable results, and to improve the MRI-based targeted biopsy and focal therapy, robust and effective validation methods for assessing system targeting accuracy are vital. The development of such a method based on the estimation of independent, anatomical-landmark-based Target Registration Errors (TREs), using a large patient dataset, will be presented.
Members of the public who would like to attend this seminar, please contact: [email protected]